Regeneron has received a second complete response letter from the FDA for odronextamab and anticipates delays for Eylea HD ...

Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.

Regeneron is having difficulties again with its manufacturing partner Novo Nordisk, reporting that it expects two FDA decisions due this month for its eye disease drug Eylea will be delayed, while ...

Delays in the decision dates for high-dose Eylea are linked to issues at a Catalent-owned facility. Once these are resolved, Regeneron expects “to receive favorable action” on these applications, CEO ...

European stocks logged their biggest one-day drop in over three months on Friday, at the end of a busy week as investors ...

Regeneron Pharmaceuticals, Inc. (REGN) reported second-quarter 2025 adjusted earnings per share (EPS) of $12.89, which ...

The Trump administration is exploring a five-year pilot program to include weight-loss drugs like Wegovy, Ozempic, Zepbound, ...

Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent ...

Weight loss medications like Wegovy can be life-changing for people living with obesity or excess weight with related health ...

The FDA had set an Aug. 19 target action date for the company's application, which was seeking a green light for Eylea HD for the treatment of macular edema following retinal vein occlusion and for ...

The introduction of GLP-1s for weight loss has been a dysfunctional mess, thanks to pharmaceutical companies, insurance plans ...

The U.S. will raise tariffs on scores of nations, effective at 12:01 a.m. on Aug. 7, according to an executive order Trump signed on Thursday. When the action is taken, the result will be ...